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Purpose: To quantify the performance of the Clarity ultrasound (US) imaging system (Elekta AB,
Stockholm, Sweden) for real-time dynamic multileaf collimator (MLC) tracking.
Methods: The Clarity calibration and quality assurance phantom was mounted on a motion platform
moving with a periodic sine wave trajectory. The detected position of a 30 mm hypoechogenic
sphere within the phantom was continuously reported via Clarity’s real-time streaming interface to an
in-house tracking and delivery software and subsequently used to adapt the MLC aperture. A portal
imager measured MV treatment field/MLC apertures and motion platform positions throughout each
experiment to independently quantify system latency and geometric error. Based on the measured
range of latency values, a prostate stereotactic body radiation therapy (SBRT) delivery was performed
with three realistic motion trajectories. The dosimetric impact of system latency on MLC tracking was
directly measured using a 3D dosimeter mounted on the motion platform.
Results: For 2D US imaging, the overall system latency, including all delay times from the imaging
and delivery chain, ranged from 392 to 424 ms depending on the lateral sector size. For 3D US
imaging, the latency ranged from 566 to 1031 ms depending on the elevational sweep. The latency-
corrected geometric root-mean squared error was below 0.75 mm (2D US) and below 1.75 mm (3D
US). For the prostate SBRT delivery, the impact of a range of system latencies (400–1000 ms) on the
MLC tracking performance was minimal in terms of gamma failure rate.
Conclusions: Real-time MLC tracking based on a noninvasive US input is technologically feasible.
Current system latencies are higher than those for x-ray imaging systems, but US can provide full
volumetric image data and the impact of system latency was measured to be small for a prostate
SBRT case when using a US-like motion input. C 2016 Author(s). All article content, except
where otherwise noted, is licensed under a Creative Commons Attribution 3.0 Unported License.
[http://dx.doi.org/10.1118/1.4955440]
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1. INTRODUCTION
Real-time dynamic multileaf collimator (MLC) tracking is an
emerging adaptive radiation therapy (RT) delivery technique
aimed at increasing dose conformity to the target by reshaping
the plan segment, i.e., MLC aperture, to the most recently
observed target position. MLC tracking is not only able to
compensate for intrafractional motion, but also implicitly
for residual interfractional setup errors which occur even
after performing modern image-guided radiation therapy.
The accuracy and timeliness (i.e., latency) of target position
data are paramount to successful tracking. The dosimetric
improvements provided by MLC tracking of the prostate
during irradiation have been illustrated for a range of frac-
tionation schedules.1 Colvill et al. demonstrated that although
the impact of intrafractional prostate motion averaged over
the entire patient cohort was found to be small, systematic
drifts and/or sudden transient motion events can lead to outlier
fractions resulting in under-dosed targets. This is especially
of concern for hypofractionated stereotactic body radiation
therapy (SBRT) delivery schedules and reduced margins.2
Prostate SBRT treatment regimes are advantageous from
a health economics and patient comfort point of view due
to the drastically reduced number of treatment fractions
and thus hospital visits. From a radiobiological point of
view, the prostate also lends itself to hypofractionation as
the linear–quadratic model predicts an improvement in the
therapeutic ratio with a reduced number of fractions since
the α/β ratio for prostate cancer is lower than the α/β
ratio for late rectal toxicity (the main dose constraint).3 For
SBRT, individual fractions which exhibit larger motion and
potential under-dosage of the target are not “averaged out”
over the small number of total fractions encompassing the
entire treatment delivery, motivating the need for active motion
management.
A variety of mostly ionizing and/or invasive target detection
modalities for intrafractional motion management has been
discussed in the literature.1,4,5 Ultrasound (US) imaging is
a potential alternative method for providing intrafractional
positional information to guide the MLC during RT.6 US
imaging is nonionizing and noninvasive, and it provides soft-
tissue detail and has the ability to provide high frame (2D) or
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volume rates (3D).7 In this study, we report on the first use
of the Clarity US imaging system (Elekta AB, Stockholm,
Sweden) for MLC-based motion tracking. To this effect,
Clarity is integrated with an in-house developed tracking and
delivery software for the Elekta Agility MLC.8
The Clarity system provides interfractional set-up correc-
tions by integrating US at the patient simulation and treatment
platform.9 3D ultrasound volumes are registered to the isocen-
ter in both the simulator and treatment rooms. The device
can also perform intrafraction monitoring during radiation
delivery with 3D images acquired via the perineum. Based
on a previously established measurement protocol,8 this study
investigates overall system latency and geometric tracking er-
ror for a range of 2D/3D imaging settings. The various latency
contributions and US motion estimation errors are calculated
from Clarity log files. The dosimetric impact of measured
latencies on the MLC tracking performance is illustrated by
delivering a clinical prostate SBRT plan to a 3D dosimeter.
2. MATERIALS AND METHODS
2.A. Dynamic MLC tracking
Dynamic real-time MLC tracking for the Agility MLC was
introduced in a previous study.8 Subsequently, DynaTrack—
the in-house developed tracking and delivery software in-
terfaced to the Agility MLC / Synergy linac via real-time
research interfaces provided by Elekta—was extended to
tracked VMAT (Ref. 10) and step-and-shoot IMRT deliveries
(Ref. 2). In the previous studies, MLC tracking was informed
by high-frequency position detection devices, either directly
by motion platform position encoders or by a simulated
electromagnetic beacon-type (e.g., Calypso) input device. In
either case, position updates were provided at a frequency
similar to the update rate of the MLC (25 Hz), leading to
continuous MLC motion. In this study, however, the lower
position update rate of the Clarity US device (≤5 Hz) required
a complete rewrite of the central MLC controller thread
(Fig. 1) which is responsible for sending updated MLC
apertures to the MLC based on the most recently detected
target position. Since MLC adjustment is now much quicker
than the time between position updates, the net effect is a
“stop-and-go” tracking mode, similar to the work performed
by Poulsen et al.,4 in which the MLC comes to a standstill
once a new target position is adapted to and no new target
position is available.
2.B. Experimental setup
The experimental setup used to investigate the performance
of Clarity US-based MLC tracking is shown in Fig. 1.
The main components were a high-precision 4D motion
platform (0.2 mm accuracy11) which was moved by a 1D
superior–inferior (SI) sine wave trajectory (20 mm peak-to-
peak, 5 s period) and the portal imager which independently
monitored the motion platform (i.e., a circular fiducial marker)
and MV treatment field trajectories.8 To avoid any impact of
the MLC leaf speed limitation on the measurements, the MLC
F. 1. Schematic representation of the experimental setup (not to scale) used
for measuring system latency and geometric tracking error (cf. Fig. 1 in
Ref. 8): fiducial marker (f.m.) and treatment beam are both visible on the
portal imager. Sample US images are shown on the right. The transversal US
image (blue color wash) is shown registered to the planning CT image of the
phantom.
was rotated to 90◦ to align the leaf travel direction with the SI
motion. It was previously shown that target motion orthogonal
to the leaf travel direction introduces an extra 10–15 ms delay
on the Agility MLC.8 For this study, the Clarity calibration
and quality assurance (QA) phantom was also placed on the
motion platform. The Autoscan transducer, supported by a
rigid mechanical arm (Manfrotto™, Italy) and attached to the
treatment couch, was positioned above the QA phantom. Water
was used as an acoustic couplant between the phantom and
transducer and to enable motion of the phantom relative to the
transducer.
2.C. Clarity ultrasound monitoring
The Clarity calibration and QA phantom which contains a
30 mm hypoechogenic sphere at 115 mm depth was imaged
with a 5 MHz abdominal Autoscan transducer (m4DC7-
3/40, Elekta Ltd.). A single 3D US image was registered
with a previously acquired CT image of the phantom in the
Clarity Automatic Fusion and Contouring () generation 4
software (AntiCosti 2015, Elekta Ltd.) and a 3D reference
positional volume (RPV) was generated based on the contour
of the 30 mm sphere in US images. Following export to the
Clarity US scanner, the   software was used to
setup and monitor the position of the RPV center-of-mass
as the phantom underwent motion. The Clarity Experimental
Monitoring (CEM) module, which permits the operator to
access imaging settings and stream monitoring data (only
available in research mode), was used to image the phantom
and send estimated RPV centroid motion to DynaTrack.
During intrafraction motion monitoring, the mechanically
swept Clarity transducer continuously scans a 3D volume
(or a single 2D frame with no mechanical sweep) and the
system estimates the rigidly shifted position of the RPV with
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T I. US imaging settings used in this study. The imaging rate is inversely
proportional to the sector size (2D) and elevational sweep (3D). The fields-
of-view (FOVs) are calculated at the depth of the sphere in the QA phantom
(115 mm).
2D 3D
Sector size (deg) 39.5–79 39.5
Sector FOV (mm) 111–255 111
Elevational sweep (deg) 0 3.6–20.8
Elevational FOV (mm) 0 8–49
Line density 192 64
Depth (mm) 150 150
Imaging rate (Hz) 47–23 13.3–2.5
a normalized cross correlation-based algorithm optimized for
low velocity prostate trajectories. The transducer position is
optically tracked within the treatment room (Polaris Spectra,
NDI, Canada) with an Elekta-devised calibration procedure
relating each US pixel to a corresponding position in room
coordinates. Further details on the intrafraction monitoring
algorithm are contained in the work of Lachaine and Falco.9
It should be noted that the motion estimation algorithms in
Clarity were designed for prostate, i.e., using Clarity for
detecting sinusoidal motion, as necessary for this study, is
outside of vendor intended operating parameters.
In the current study, the ultrasound transducer sweep
(elevational) axis was aligned with the right–left (RL) axis,
while the lateral axis was aligned with the direction of motion
(SI). The CEM module was used to investigate the effect of
various 2D and 3D imaging parameters (Table I) on the total
system latency. Additionally, the amplitude and period of the
sine wave trajectory were varied for one of the 2D US imaging
settings (sector size: 59.3◦) to investigate the possible impact
of maximum target speed on system latency.
2.D. Definitions: Latency and geometric tracking error
System latency τsys was defined as the overall time delay
between when a new target position was realized and when the
MLC was fully adapted to it. It included contributions from
both the Clarity and the Agility systems. From Poulsen et al.,4
we adopt the following notation for system latency:
τsys= ⟨TUS⟩+0.5× ⟨∆Timage⟩+0.5× ⟨τMLC⟩. (1)
TUS is the latency contribution of the Clarity system
including image acquisition, motion estimation, and the
transfer of the detected target position to DynaTrack. ⟨∆Timage⟩
is the inverse position update rate of the Clarity system, i.e.,
the average time interval between new position estimates
(not to be confused with the inverse imaging rate). It is
calculated from log files saved during monitoring by the
CEM module containing system timestamped displacement
data points. 0.5× ⟨∆Timage⟩ corresponds to the mean waiting
time between a change in target position and its observation
by the Clarity system. ⟨τMLC⟩ is the mean MLC adjustment
latency, i.e., the time delay between requesting a new MLC
position and reaching it.
To exclude the effect of system latency on geometric track-
ing error, the latency-corrected (τ-less) root-mean squared









Here, N denotes the number of data points, sfm= (0,ySI,0)T
the motion platform (i.e., fiducial marker) trajectory as a
function of time t, and sfield the latency-corrected center-of-
mass trajectory of the MV treatment field (s in IEC 61217 coor-
dinates). Excluding the effect of latency effectively assumes
perfect motion prediction12 and is thus an idealized scenario.
It is nonetheless instructive, as it allows us to isolate the
error contributions of Clarity’s motion estimation algorithm,
the effect of under-sampling the motion, and the MLC leaf
adjustments. System latency [Eq. (1)] and geometric tracking
error [Eq. (2)] are measured by automatically identifying sfm
and sfield directly from the sequence of portal images acquired
during each experiment.8 The system latency corresponds
to the phase shift between the sine wave trajectories fitted
to the motion platform and MV treatment field trajectories,
respectively. The geometric tracking error corresponds to the
(averaged) latency-corrected geometric distance of the two
trajectories. The accuracy of the motion platform, RMSEMP,
was validated for each run by comparing the imager-derived
motion platform trajectory sfm with the input trajectory sent
to the platform. A subset of these measurements was repeated
with a load of 24 kg, equivalent to the weight of the 3D
dosimeter (described below in Sec. 2.E).
To further quantify the motion estimation error of the
Clarity system, RMSEUS was calculated for the realistic 3D
prostate trajectories (cf. Sec. 2.E) by comparing the (latency-
corrected) target positions reported by Clarity with the motion
platform trajectories. For the prostate trajectories, this was
done using the CIRS Model 053 US prostate phantom (CIRS,
Inc., Norfolk, USA), submerged in a water container, to allow
for full 3D motion with the transducer remaining stationary.
2.E. Dosimetric impact of US-based MLC tracking
To assess the dosimetric impact of a range of different
system latencies (400, 600, and 1000 ms) for a typical prostate
SBRT patient (PTV = 104 cc, RTOG 0938 planning guide-
lines, 6 MV, 7 equidistant beams, 2◦ collimator), an additional
verification experiment was performed. The Delta4 diode array
(Scandidos, Uppsala, Sweden)13 was placed on the motion
platform previously used for the Clarity phantom. Three
different delivery and motion scenarios were tested: (i) static—
no motion/no tracking, (ii) conventional—motion/no tracking,
and (iii) tracked—motion/tracking. Three different previously
recorded motion traces were used: a baseline drift posteriorly
and inferiorly (continuous drift), a baseline drift posteriorly
and inferiorly with sudden transient motion mostly anteriorly
(erratic), and a slow baseline drift anteriorly and superiorly
with sudden transient motion anteriorly and superiorly (high
frequency).2 All traces were normalized to start at the isocenter.
The 400 s motion traces were used as inputs for the motion
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platform. Direct 3D US monitoring was not deemed feasible
in this setup as we could not simultaneously accommodate
the Delta4 and the US phantom on the motion platform
due to space limitations. Instead, actually achieved platform
positions, as measured by the internal position encoders of the
motion platform, were reported toDynaTrack via a direct UDP
network link.8 These target positions were then artificially
queued in DynaTrack to achieve the desired overall system
latency.10 Deliveries were reproducibly started within a few
seconds from the beginning of the motion trace. Resulting
3D dose distributions were compared in the Delta4 software
by means of a global gamma analysis (1%/1 mm, 2%/2 mm
and 3%/3 mm). For all cases, the measurement from the
static delivery was used as reference dose distribution. The
dose measured at the isocenter of the static delivery was
used as a reference value for the gamma analysis and voxels




Figure 2 summarizes the latency findings for all US
imaging settings. ⟨TUS⟩ is calculated from Eq. (1) and assumes
⟨τMLC⟩ = 30 ms.8 For the 2D acquisitions, system latency
increases moderately with sector size. ⟨∆Timage⟩, as logged
by the Clarity log files, appears to be independent of the
sector size, suggesting that the average time between position
updates calculated by Clarity is not affected by the increase in
2D US image size. The inverse imaging rate is below 50 ms
for all sector sizes, indicating that motion estimation time
is the main cause for delay on the imaging side. For the
3D acquisitions, system latency increases linearly (R2= 0.94)
with elevational sweep. ⟨∆Timage⟩ increases strongly between
∼3◦–10◦ elevational sweep but appears to plateau for larger
sweep angles despite the linear (R2 = 0.99) increase in the
inverse imaging rate. It should be noted that Clarity uses
F. 2. System latency, its individual components [Eq. (1)], and inverse
imaging rate for US-based MLC tracking of a sine wave trajectory as a
function of US sector size (2D) and elevational sweep (3D).
F. 3. System latency for US-based MLC tracking of different sine wave
trajectories as a function of maximum target speed. Period is encoded by line
style: 5 s (solid), 4 s (dashed), and 3 s (dotted).
partially updated 3D volumes for position estimation and that
Eq. (1) is derived for a scenario where the image acquisition
time is much smaller than the inverse position update rate. For
large sweep angles, this assumption is clearly violated.
Parameter selection for the sine trajectory has a visible
impact on system latency (Fig. 3) as measured with one of
the 2D US imaging settings. Neither amplitude nor period
is a clear predictor for system latency, but the relationship
between maximum target speed and system latency is weakly
linear (R2= 0.69).
3.B. Geometric tracking error
Figure 4 highlights the different geometric errors derived
from our experimental setup as a function of the US sector
F. 4. Latency-corrected geometric tracking error (RMSEτ-less) and motion
platform accuracy (RMSEMP) for US-based MLC tracking of a sine wave
trajectory as a function of US sector size (2D) and elevational sweep (3D).
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F. 5. Worst case geometric distortions during a full 5 s period as observed in the slowest 3D US acquisition (elevational sweep angle: 20.8◦). The image size
corresponds to the FOV at the depth of the sphere.
size and elevational sweep. For 2D acquisitions, the latency-
corrected geometric displacement between fiducial marker
and MV treatment field (RMSEτ-less) is shown to increase
moderately with sector size. For 3D acquisitions, the increased
latency also translates into a larger RMSEτ-less compared to
the 2D acquisition. Here, the tracking error increases linearly
(R2= 0.97) with elevational sweep.
The accuracy of the motion platform (RMSEMP) is
measured to be <0.35 mm which essentially corresponds
to the effective pixel resolution of the portal imager at the
isocenter. The largest geometric mismatch between the motion
platform input trajectory and actual trajectory occurred at the
respiratory extrema where the platform tended to exceed the
prescribed motion amplitude. As expected, RMSEMP, which
is estimated independently from the Clarity system, does not
depend on the US imaging settings. Introducing an additional
weight of 24 kg had no discernible impact on the accuracy of
the motion platform.
The RMSEUS averaged over all realistic 3D prostate
trajectories (Sec. 2.E) was 0.7±0.2 mm (2D US), 0.6±0.1 mm
(3D US, smallest elevational sweep), and 0.7±0.2 mm (3D
US, largest elevational sweep), respectively. For the 2D
acquisitions, out-of-plane RL motion could not be resolved
and produced the largest error contribution.
3.C. Geometric image distortions
For 3D US imaging with large elevational sweeps and
thus correspondingly low imaging rates, there is a danger
that interplay between target and transducer motion will lead
to artifact-ridden images which could result in incorrectly
assigned target positions.14 By looking at a worst case scenario
of 20.8◦ elevational sweep angle, we were able to quantify the
image distortions in the lateral/elevational plane at an axial
depth corresponding to the center of the hypoechogenic sphere
(Fig. 5). Given the size of the spherical inclusion (30 mm), the
F. 6. Average gamma failure rate for three prostate motion trajectories.
Some bars are zero and thus not visible.
elevational FOV (49 mm), the inverse imaging rate (394 ms),
and a maximum target speed of 12.6 mm/s, a maximum
distortion of 3 mm is expected between the opposing edges
of the spherical inclusion. Using Otsu thresholding,15 the
inclusion area varied by 3.6% (mean) over the course of the
entire period compared to the first image of the series. As
expected, the maximum deviation (8.4%) occurred between
the sinusoid extrema when target motion was at its maximum.
The Dice similarity coefficient16 was 0.94±0.03 averaged over
the entire period with the lowest score (0.91) occurring on the
opposite extrema of the sinusoid.
3.D. Dosimetric impact of ultrasound-based tracking
The gamma failure rates for a typical prostate SBRT
patient subject to either a conventional delivery or tracked
deliveries (with different overall system latencies) based
on three different motion trajectories are shown in Fig. 6.
Regardless of the motion trajectory, the gamma failure of the
conventional delivery increases dramatically when going from
3%/3 mm toward 1%/1 mm. For the tracked deliveries, the
dosimetric effect of all investigated latencies appears minimal
and the average gamma failure is around 2% at 1%/1 mm.
4. CONCLUSIONS
To our knowledge, this is the first experimental study
demonstrating the feasibility of US motion estimation to guide
dynamic MLC tracking on a research radiotherapy treatment
platform. The overall system latency, including all delay times
from the imaging and delivery chain, ranged from 392 to
424 ms (2D US) depending on lateral sector size and from
566 to 1031 ms (3D US) depending on elevational sweep.
Varying the sine wave trajectory parameters (amplitude and
period) introduced another small modulation to the latency.
Similar to previous observations,8 increases in the maximum
target speed yielded increases in latency as well. The average
latency-corrected tracking RMSE was below 0.75 mm (2D
US) and below 1.75 mm (3D US). Fledelius et al.17 have
reported system latencies of 264 ms (382 ms) for kV (MV)
x-ray based MLC tracking. While Clarity-based MLC tracking
has a higher delay time, especially for 3D image acquisitions,
US imaging is nonionizing and does not require implanted
markers.
2D US allows for a faster response of the MLC to motion
but it requires prior knowledge about the orientation of motion
if out-of-plane motion is to be minimized. An exploratory
analysis of latency-corrected US-only RMSE for three realistic
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prostate trajectories confirmed that out-of-plane motion (in RL
direction in this study) poses a challenge for 2D US imaging.
When using 3D US imaging, employing even the smallest
elevational sweep angle of 3.6◦ improved the RL resolution
visibly.
Measuring latency requires a controlled and thus artificial
experimental setup. Results should nevertheless be applicable
to in-vivo patient imaging as long as the target can be reliably
detected in the US images. In terms of geometric accuracy,
the transition to in-vivo images is expected to have a greater
impact due to the anticipated decrease in contrast compared
to the relatively simple US phantoms employed in this study.
Although beyond the scope of this study, the determination of
position estimation accuracy in-vivo against a gold standard
method such as x-ray imaging with fiducials needs to be
addressed before any US-based MLC tracking system can
be introduced into the clinic.
The potential dosimetric impact of a US-like range of
system latencies (400–1000 ms) on the performance of MLC
tracking was found to be minimal for a prostate SBRT case
subject to three realistic motion conditions. MLC-based track-
ing for prostate SBRT with current 3D ultrasound transducer
technology appears to be feasible but the intrafractional target
detection accuracy needs to be validated with patient data. If
US imaging was applied to organs dominated by respiratory
motion (something the Clarity motion estimation algorithm
is not optimized for in its current form), the latency and
corresponding geometric beam-target misalignment would
need to be reduced by speeding up image acquisition,
motion estimation times. and/or employing motion prediction
algorithms.12 For comparatively slow 3D US acquisitions, the
interplay between target and transducer mechanical sweep
was shown to lead to small but measurable image distortions
for a fast sine wave trajectory. One obvious solution to this
problem could be the 2D matrix array transducer technology.
Bell et al.18 have reported on the use of such a probe without
mechanically swept components for in-vivo liver imaging. For
a 3D imaging volume (∼14 cm×6 cm×7 cm) slightly smaller
than the volume used in this study, they achieved an imaging
rate of 24 Hz.
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